215 related articles for article (PubMed ID: 24802963)
1. Treatment of Graves' disease with methimazole in children alters the proliferation of Treg cells and CD3+ T lymphocytes.
Klatka M; Kaszubowska L; Grywalska E; Wasiak M; Szewczyk L; Foerster J; Cyman M; Rolinski J
Folia Histochem Cytobiol; 2014; 52(1):69-77. PubMed ID: 24802963
[TBL] [Abstract][Full Text] [Related]
2. Th17 and Treg cells in adolescents with Graves' disease. Impact of treatment with methimazole on these cell subsets.
Klatka M; Grywalska E; Partyka M; Charytanowicz M; Kiszczak-Bochynska E; Rolinski J
Autoimmunity; 2014 May; 47(3):201-11. PubMed ID: 24443787
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
[TBL] [Abstract][Full Text] [Related]
4. Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease.
Bossowski A; Urban M; Stasiak-Barmuta A
Pediatr Res; 2003 Sep; 54(3):425-9. PubMed ID: 12761360
[TBL] [Abstract][Full Text] [Related]
5. Methimazole upregulates T-cell-derived cytokines without improving the existing Th1/Th2 imbalance in Graves' disease.
Kocjan T; Wraber B; Kocijancic A; Hojker S
J Endocrinol Invest; 2004 Apr; 27(4):302-7. PubMed ID: 15233546
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory role of vitamin D and selenium supplementation in newly diagnosed Graves' disease patients during methimazole treatment.
Gallo D; Bruno A; Gallazzi M; Cattaneo SAM; Veronesi G; Genoni A; Tanda ML; Bartalena L; Passi A; Piantanida E; Mortara L
Front Endocrinol (Lausanne); 2023; 14():1145811. PubMed ID: 37124743
[TBL] [Abstract][Full Text] [Related]
7. Impact of treatment with methimazole on the Bcl-2 expression in CD8+ peripheral blood lymphocytes in children with Graves' disease.
Klatka M; Grywalska E; Polak A; Roliński J
Ann Agric Environ Med; 2013; 20(4):884-8. PubMed ID: 24364474
[TBL] [Abstract][Full Text] [Related]
8. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
9. Impaired immune regulation after radioiodine therapy for Graves' disease and the protective effect of Methimazole.
Côté-Bigras S; Tran V; Turcotte S; Rola-Pleszczynski M; Verreault J; Rottembourg D
Endocrine; 2016 Jun; 52(3):587-96. PubMed ID: 26701678
[TBL] [Abstract][Full Text] [Related]
10. Abnormal distribution of gammadelta T lymphocytes in Graves' disease and insulin-dependent diabetes type 1.
Kretowski A; Myśliwiec J; Kinalska I
Arch Immunol Ther Exp (Warsz); 2000; 48(1):39-42. PubMed ID: 10722230
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism.
Sato S; Noh JY; Sato S; Suzuki M; Yasuda S; Matsumoto M; Kunii Y; Mukasa K; Sugino K; Ito K; Nagataki S; Taniyama M
Thyroid; 2015 Jan; 25(1):43-50. PubMed ID: 25178068
[TBL] [Abstract][Full Text] [Related]
12. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
13. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease.
Nakamura H; Noh JY; Itoh K; Fukata S; Miyauchi A; Hamada N
J Clin Endocrinol Metab; 2007 Jun; 92(6):2157-62. PubMed ID: 17389704
[TBL] [Abstract][Full Text] [Related]
14. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
Corrales JJ; López A; Ciudad J; Mories MT; Miralles JM; Orfao A
J Endocrinol; 1997 Dec; 155(3):491-500. PubMed ID: 9487994
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
Huang CN; Hsu TC; Chou HH; Tsay GJ
J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
[TBL] [Abstract][Full Text] [Related]
16. Impact of methimazole treatment on magnesium concentration and lymphocytes activation in adolescents with Graves' disease.
Klatka M; Grywalska E; Partyka M; Charytanowicz M; Rolinski J
Biol Trace Elem Res; 2013 Jun; 153(1-3):155-70. PubMed ID: 23661330
[TBL] [Abstract][Full Text] [Related]
17. Neutropenia Occurs More Often Under Carbimazole than Under Methimazole Treatment in Pediatric Graves' Disease Patients.
Schempp V; Cebeci AN; Reinauer C; Woelfle J; Dörr HG; Roosen MT; Gohlke J; Gohlke B
Thyroid; 2024 Jun; 34(6):735-743. PubMed ID: 38613811
[No Abstract] [Full Text] [Related]
18. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
20. Substituting Potassium Iodide for Methimazole as the Treatment for Graves' Disease During the First Trimester May Reduce the Incidence of Congenital Anomalies: A Retrospective Study at a Single Medical Institution in Japan.
Yoshihara A; Noh JY; Watanabe N; Mukasa K; Ohye H; Suzuki M; Matsumoto M; Kunii Y; Suzuki N; Kameda T; Iwaku K; Kobayashi S; Sugino K; Ito K
Thyroid; 2015 Oct; 25(10):1155-61. PubMed ID: 26222916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
